gdc
FDA Approvals, News & UpdatesLeukemiaNewsworthy

Tibsovo First Drug Approved by the FDA for AML with IDH1 Mutation

In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
October 2018 Vol 4 No 5

In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation. On the same day, the FDA approved the RealTime IDH1 test, which is designed to identify the IDH1 mutation. Tibsovo should be used in patients after they had the RealTime IDH1 genetic test to confirm that they have that mutation.

“Tibsovo is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH1 mutation,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. “The use of Tibsovo is associated with a complete remission in some patients and a reduction in the need for both red cell and platelet transfusions.”

This approval was based on a clinical trial of 174 adults with relapsed or refractory AML and a confirmed IDH1 mutation. In about 32% of the patients, the cancer was in complete remission after receiving Tibsovo. It took an average of 2 months to respond to this treatment, and the remission lasted an average of 8.2 months.

Among the most common side effects with Tibsovo were fatigue, increase in white blood cells, joint inflammation/pain, diarrhea, shortness of breath, nausea, mucositis, fever, cough, and constipation.

Recommended For You
FDA Approvals, News & Updates
FDA NEWs
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Leukemia
Considering the Role of Oral Targeted Therapies in the Treatment of Patients with Leukemia
By Chase Doyle
Just because a cancer drug is approved by the FDA does not mean its therapeutic benefit is completely understood. Improving outcomes and minimizing side effects of a drug often requires using the drug in different doses or in combination with other drugs.
Leukemia
Long-Term Data Support the Use of Calquence for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
By Chase Doyle
The targeted therapy Calquence (acalabrutinib), a Bruton tyrosine kinase (or BTK) inhibitor, which is approved by the FDA for the treatment of patients with non-Hodgkin lymphoma has now demonstrated long-term remissions as first-line treatment of patients with chronic lymphocytic leukemia (CLL), according to data presented at the 2020 ASCO annual meeting.
Last modified: October 27, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country